What Are Clinical Trial Requirements for Corporate Sponsors?

The IND application requires sponsors to submit detailed information about the drug's chemistry, manufacturing, nonclinical laboratory and animal testing data, and a proposed clinical protocol. The FDA reviews the application to determine whether the proposed trial can proceed without unreasonable risk to participants. If the FDA does not respond within 30 days, the IND becomes effective by default, but this does not eliminate sponsor liability for safety or protocol compliance. Sponsors must also maintain an IND throughout the trial and update it whenever material changes occur, such as new safety data or protocol amendments.

An IRB must review and approve the protocol, ICF, and investigator qualifications before enrollment begins. In New York, IRBs are regulated under state law and must comply with federal Common Rule standards. IRBs in New York often require sponsors to demonstrate that the trial design minimizes risk and that the informed consent process is genuinely informed, not merely compliant with template language. From a practitioner's perspective, delays in IRB review or requests for protocol modifications can significantly extend the pre-trial timeline, and sponsors should anticipate iterative feedback cycles rather than single-submission approvals. Documentation of IRB communications and approval dates becomes critical evidence if a participant later claims inadequate notice or safety oversight.

Sponsors must establish a safety monitoring system and report serious adverse events (SAEs) to the FDA and IRBs within specified timeframes. Unexpected serious adverse reactions typically require reporting within 15 calendar days. Failure to report, or delayed reporting, can trigger FDA enforcement action, trial holds, or criminal liability in egregious cases. Sponsors should also maintain a detailed adverse event database and conduct regular safety reviews to identify trends that might warrant protocol modifications or trial termination. Courts and regulatory bodies scrutinize whether sponsors acted promptly and transparently when safety signals emerged.

Sponsors must maintain comprehensive trial records, including case report forms, source documents, correspondence with investigators and IRBs, and safety reports. These records are subject to FDA inspection and may be subpoenaed in litigation. New York courts have examined sponsor record-keeping practices in cases involving participant injury, and incomplete or delayed documentation often undermines a sponsor's defense. Sponsors should establish clear protocols for document retention, version control, and accessibility to ensure that records are complete and retrievable if regulatory or legal challenges arise.

The FDA conducts pre-approval and post-approval inspections of sponsor facilities, contract research organizations (CROs), and investigator sites. If inspectors identify significant violations, the FDA may issue a warning letter, place the trial on clinical hold, or refer the matter to the Department of Justice for criminal prosecution. Sponsors should prepare for inspections by conducting internal audits, ensuring that standard operating procedures are current and followed, and maintaining clear communication logs with investigators and CROs. Proactive compliance reduces the likelihood of enforcement but does not eliminate litigation risk.

Participants injured during a trial may sue the sponsor for negligence, breach of warranty, or failure to warn. These claims often hinge on whether the sponsor adequately disclosed risks in the ICF and whether the trial design itself was reasonable. Courts may also consider whether the sponsor failed to monitor safety adequately or failed to terminate the trial when safety signals emerged. Unlike regulatory proceedings, civil litigation places the burden on the sponsor to demonstrate that it exercised reasonable care; juries may hold sponsors to a higher standard if they perceive that profit motives influenced safety decisions. Sponsors should work with counsel experienced in clinical trial litigation to assess exposure and develop defense strategies early.